Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Relay Therapeutics reports promising early results for its experimental drug RLY-2608 in treating hard-to-treat breast cancers, showing tumor shrinkage and a good safety profile.
Relay Therapeutics reports early positive results from a trial of its experimental drug RLY-2608 in treating difficult-to-treat breast cancers, including triple-negative and hormone receptor-positive types.
The drug, which targets a protein linked to cancer growth, caused significant tumor shrinkage in some patients, with partial or complete responses observed.
Presented at a medical conference, the findings highlight RLY-2608’s potential as a new treatment option for patients who have exhausted standard therapies, along with a favorable safety profile in early testing.
While still in early development, the data have sparked optimism, prompting Relay to advance the drug into larger trials.
Further research is needed to confirm long-term effectiveness and safety.
Relay Therapeutics informa de los primeros resultados prometedores de su fármaco experimental RLY-2608 en el tratamiento de cánceres de mama difíciles de tratar, mostrando una reducción del tumor y un buen perfil de seguridad.